EPS Creative Health Technology Group Limited provided unaudited consolidated earnings guidance for the six months ended 30 September 2023. For the period, Group expects to record a loss of approximately HKD 4 million for the Period, as compared to a loss of approximately HKD 20 million for the corresponding period in 2022. The expected reduction in loss was mainly attributable to the gain on revaluation of the promissory note issued for the acquisition of the 65% equity interests in R&E Corporation Limited, the details of which are set out in the announcement of the Company dated 28 March 2023, for the Period.